Precision vs Imprecision Oncology (White Paper)

White Paper

July 30, 2021

Download pdf

Precision vs Imprecision Oncology
Jeffrey M. Bockman, PhD, EVP, Head of Oncology Practice
Cello Health BioConsulting.

I got to thinking recently about the push towards developing drugs for molecularly stratified patientpopulations, including a spate of approvals over the past few years for agents targeting aberrantly expressed(mutated, translocated, amplified, etc.) proteins, as opposed to many of the blockbuster drugs (based on WWsales—see data above from EvaluatePharma) that are not “precision medicine” agents….More by clicking the Download pdf green button above.